Top Artificial Intelligence-Based Healthcare Mobile Apps and Their Use Cases

Endocrinology and Metabolic Disorders

Toujeo to treat Type 1 Diabetes; TauRx for Alz...

Sanofi’s Toujeo has received FDA recommendation for its expanded use in Type 1 Diabetes. Toujeo is an insulin glargine injection to control the highs and lows of blood sugar in the body. Indicated ...

Nov 28, 2019

Pharma news
GHO to advance healthcare in Europe; Truvian nets USD 27.1 Mn; Lilly plans its diabetes portfolio expansion

Global Healthcare Opportunities (GHO) Capital, a London-based healthcare investment firm, has recently netted USD 1.1 Billion to advance European healthcare. The company plans to use the proceeds to invest in healthcare companies. Closure of the second round capped at USD 1.1 Billion (Euro 975 Million) is the l...

Find More
Pharma news
Nordisk ties up with Dicerna; Pfizer’s drug gets FDA nod

Novo Nordisk has announced to enter into a collaboration with Dicerna’s RNAi platform to focus on metabolic and liver-related diseases. The companies will be focusing to advance the treatment landscape of the diseases such as non-alcoholic steatohepatitis (NASH), Type 2 diabetes and obesity. Nordisk will be inv...

Find More
World Diabetes Day
World Diabetes Day | 2019

World Diabetes Day, observed on 14 November every year, aiming to raise awareness about the impact that diabetes has on the family. This year, the theme this day is Family and Diabetes. World Diabetes Day  According to a survey by WHO, 425 million people are still struggling with diabetes, and by th...

Find More

More Views & Analysis

Pharma news
FDA declines the approval of Lipocine’s testosterone drug; Novartis Sandoz to buy Aspen Pharmacare Japanese Unit

The US FDA for the third time has refused to give approval to Lipocine’s oral testosterone drug, Tlando. The drug is an oral testosterone replacement therapy in clinical trials for the treatment of Primary and Secondary hypogonadism in males. The drug contains containing Testosterone Undecanoate (TU) which help...

Find More

Pharma news
Evotec, Vifor Pharma collaborates to cure kidney diseases; AZ takes major steps to advance pharma and medicine R&D in China; Amneal licenses-in a Myasthenia Gravis drug from Kashiv BioSciences

Switzerland-based Vifor Pharma and Germany-based Evotech AG have collaborated for the development and discovery of new treatments for kidney diseases. The launch of a new 50:50 joint venture will be focused on developing nephrology pipeline utilizing Evotec’s UK kidney biobank, NURTuRE. Under the terms of the a...

Find More

First oral GLP-1 treatment approved for type2 Diabetes

The US FDA has approved Rybelsus (semaglutide) oral tablets to improve blood sugar in adult patients with Type II Diabetes. Rybelsus is an oral glucagon-like peptide (GLP-1) receptor protein treatment which has been approved after 15 years of the approval first GLP-1 agonist. GLP-1 is a hormone found in insuffi...

Find More

Hypoparathyroidism Drugs
Hyperthyroidism Treatment Market and Drugs

Hypoparathyroidism is a rare endocrine condition marked by low-calcium and high-phosphate levels as compared to a normally lower or inappropriate level of normal Parathyroid hormone (PTH). Understanding of the Hypoparathyroidism epidemiological data become difficult, considering that the country-specific data i...

Find More

Pharma News
Fujifilm acquires global rights to Cynata’s novel therapy for GvHD; Themis raises EURO 40 million for Chikungunya vaccine; Bayer to license One Drop’s digital diabetes platform

FUJIFILM Corporation has signed an exclusive licensing agreement with an Australian bio-venture Cynata Therapeutics Limited for CYP-001. Under the agreement, FUJIFILM will gain rights to develop, manufacture and market a drug for the treatment of graft-versus-host disease (GvHD). CYP-001 is a Cynata’s lead cand...

Find More

Pharma news
Genenta Sciences raises USD 14.54M; GSK announces to buy Sitari Pharmaceuticals; Mallinckrodt to Sell BioVectra for USD 25M; Lexicon to receive USD 260M from terminated diabetes partnership 

Mallinckrodt has announced to sell its Canadian drug manufacturing BioVectra Inc. to a Miami-based private equity firm, an affiliate of H.I.G. Capital for approximately USD 250 Million. The agreement included a fixed amount of USD 175 Million, with an upfront amount of USD 135 Million, a long term payment of US...

Find More

Rheumatoid Arthritis (RA) is a chronic, inflammatory autoimmune disease that leads to progressive an.....

Find More

A formal medical disorder affecting approximately 10 percent of the world population is trypanophobi.....

Find More

Wet Age-related Macular Degeneration (Wet-AMD) also referred to as Neovascular AMD (nAMD), is the mo.....

Find More

A rare autosomal recessive disorder, Familial chylomicronemia syndrome (FCS), affects 1 in 1 to 2 mi.....

Find More

Gout is a chronic disease caused by the deposition of monosodium urate (MSU) crystals in joints. It .....

Find More

Anorexia is the loss of the desire to eat, whereas cachexia results from the skeletal muscle mass in.....

Find More